NEW YORK – Centogene said on Tuesday that it is teaming up with Alnylam Pharmaceuticals on a clinical biomarker study of hereditary transthyretin-related amyloidosis (ATTRv).
The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene, which encodes transthyretin, formerly known as prealbumin. Mutated Ttr proteins get misfolded, which results in transthyretin amyloidosis.